$ARFXF on fire after biogen news
still a long way to run
ProMIS Neurosciences makes a more selective and specific antibody than Biogen's aducanumab. Aducanumab is limited by brain swelling effects but has shown some clinical benefit, hence FDA approval today and a boost in their market cap by about $10-15 BILLION in just an hour.
ARFXF (ProMIS) makes PMN310 which can be dosed at higher levels. The company has been pre-phase I for a while, and shareholders were told that PHI funding was contingent on FDA approval of aducanumab.
Here's the real kicker... PMN's market cap is only $60M... which is peanuts compared to the market opportunity.
$ARFXF
glta
God grant me the serenity to deal with the things I cannot change; courage to change the things I can and should; and wisdom to know the difference.